[ad_1]
Of special concern in the last hours after the announcement of the death of a volunteer who participated in the clinical trial of the vaccine prepared by AstraZeneca and the University of Oxford for the coronavirus, given the need for a saving vaccine to put an end to the nightmare.
The volunteer died in Brazil on Monday, however the news of his death was released on Wednesday afternoon without further details being known.
Brazil’s Anvisa health service said in a statement that a Covid-19 vaccine volunteer developed by AstraZeneca and the University of Oxford had died, while Brazilian media reported that the death was due to complications from the coronavirus.
However, the service did not provide official details about the death of the volunteer, citing the secrecy of the protocols. 
He did not participate in the active part of the clinical trial of the vaccine.
According to information from the agency Bloomberg, the volunteer had not received the vaccine but a placebo vaccine, the so-called placebo.
According to a source familiar with the case, the clinical trial of the vaccine would have been stopped if the deceased volunteer had participated in its active part.
Therefore, this statement may mean that the unfortunate man was in the control group, that is, he did not receive the Covid-19 vaccine but another meningitis vaccine.
The test participants do not know which group they belong to, whether they are receiving the vaccine or a placebo.
In any case, an official confirmation from the company is awaited. 
Testing continues
According to the Brazilian authorities, the clinical trial of the vaccine will continue despite the death of the volunteer.
Oxford is not concerned about the safety of the vaccine trial and Brazilian regulators have recommended that it continue, said Stephen Rouse, the university’s director.
Meanwhile, a clinical trial of the vaccine in the US has been on hold for more than a month. Studies were stopped around the world in September when a British volunteer fell ill, but have resumed in the UK, Brazil, South Africa and India in recent weeks.
However, since pauses in vaccine studies are common, AstraZeneca and Oxford are under intense pressure to reveal more information about complications in the UK.
[ad_2]
